Small molecule · Inhibitor · developed by OPKO Health
ELND005 (scyllo-inositol, also called scyllitol) is an oral stereoisomer of inositol that crosses the blood-brain barrier. It is reported to inhibit amyloid beta plaque formation in the brain, though its precise mechanism is not established. It is studied in Alzheimer's disease and Down syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01791725 | Phase 2 | Down Syndrome | Completed | OPK |
| NCT01766336 | Phase 2 | Alzheimer's Disease | Terminated | OPK |
| NCT00934050 | Phase 2 | Alzheimer's Disease | Completed | OPK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer's DiseaseDown Syndrome
Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.
See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OPK catalysts and pipeline →